Impact of different sequencing strategies of talazoparib and carboplatin combination upon efficacy and toxicity in BRCA-wild type and BRCA-mutant triple-negative breast cancer models

• Published in: Journal of clinical oncology Vol. 39; no. 15_suppl; p. 586
• Main Authors: Beniey, Michele, Cotte, Alexia, Hubert, Audrey, Bechir, Nelly, Haque, Takrima, Tran-Thanh, Danh, Hassan, Saima Noor
• Format: Journal Article
• Language: English
• Published: 20.05.2021

Abstract only 586 Background: PARP inhibitors (PARPi) such as talazoparib and olaparib, have demonstrated an improvement in progression-free survival (PFS) amongst metastatic HER2-negative breast cancer patients with germline mutations in BRCA1/2 (BRCA-MUT). Clinical trials have evaluated PARPi in c...